TABLE 3.

AEs associated with CQ/HCQ administration were reported in two clinical trials and three observational studies where COVID-19 patients were given either CQ or HCQ in combination with standard of care drugs.

Drug/Location/References	Clinical Trial No./PubMed No	AEs Reported
Chloroquine (Rosenberg et al., 2020)	PMID: 32236562	Vomiting; abdominal pain; nausea; diarrhea; rash/itchiness; cough; shortness of breath
Chloroquine (Borba et al., 2020)	NCT04323527 PMID: 32330277	Decreased hemoglobin; increased creatinine; increased CK; increased CKMB; QTcF >500 m; ventricular tachycardia
Hydroxychloroquine (Tang et al., 2020)	PMID: 32409561	Diarrhea; vomiting; nausea; abdominal discomfort; thirst; sinus bradycardia; hypertension; orthostatic hypotension; hypertriglyceridemia; decreased appetite; fatigue; dyspnoea; flush; kidney injury; coagulation dysfunction; blurred vision; decreased WBC; increased alanine aminotransferase; increased serum amylase; decreased neutrophil count; disease progression*; upper respiratory tract*
Hydroxychloroquine (Rosenberg et al., 2020)	PMID: 32392282	Diarrhea; hypoglycemia; cardiac arrest*; abnormal ECG*; arrhythmia*; QT prolongation*
Hydroxychloroquine (RECOVERY Group, (Group et al., 2020)	NCT04381936	Atrial flutter/fibrillation, other supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, atrioventricular block requiring intervention

Serious AEs, as defined by the respective study investigators, are marked with *.